High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The objective of this paper is to investigate the mesothelin expression level to the clinicopathological features, chemoresponse, and to the outcome of patients with epithelial ovarian carcinoma (EOC). Mesothelin mRNA was detected by real-time quantitative reverse-transcription PCR in 139 EOC patients. Clinical characteristics, histopathological items, responses to chemotherapy, progression-free survival (PFS), and overall survival (OS) were recorded. Tumours with advanced stages had higher mesothelin than those with early stages. The chemoresistant patients showed significantly higher mesothelin than did chemosensitive patients (2.81 vs 0.43, P<0.001), irrespective of optimal or suboptimal surgery in those with advanced stages. Highly expressed levels of mesothelin were an independent but poor prognostic factor in the PFS (2.03 (1.23-3.37) P=0.006) and OS (3.72 (1.64-8.45), P=0.002) of the 139 EOC patients in multivariate analysis. In addition, patients in advanced stages with highly expressed mesothelin also had significantly worse OS, regardless of whether they had undergone optimal (13.85 (1.76-125.60), P=0.013) or suboptimal (4.47 (1.83-10.88), P=0.001) debulking surgery in multivariate analysis. Out results provide new evidence that mesothelin expression is associated with chemoresistance and with shorter disease-free survival and worse OS of patients with EOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Cited by
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan, R., Thomas, A., Alewine, C., Le, D. T., Jaffee, E. M., & Pastan, I. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3672 · Cited by 325
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
The immunopeptidomic landscape of ovarian carcinomas
Schuster, H., Peper, J. K., Bösmüller, H.-C., Röhle, K., Backert, L., Bilich, T., Ney, B., Löffler, M. W., Kowalewski, D. J., Trautwein, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707658114 · Cited by 189
“We could show that MSLN staining is directly correlated with MUC16 staining, and it has been further reported that high MSLN expression is a negative prognostic factor in EOC (51).”
BackgroundMesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways
Chang, M.-C., Chen, C.-A., Chen, P.-J., Chiang, Y.-C., Chen, Y.-L., Mao, T.-L., Lin, H.-W., Lin Chiang, W.-H., & Cheng, W.-F. (2012) · Biochemical Journal · doi:10.1042/bj20110282 · Cited by 165
Self-citation
Metadata
- Authors
- Cheng, W.-F., Huang, C.-Y., Chang, M.-C., Hu, Y.-H., Chiang, Y.-C., Chen, Y.-L., Hsieh, C.-Y., & Chen, C.-A.
- Venue
- British Journal of Cancer
- Published
- 2009-03-17
- Volume
- 100
- Issue
- 7
- Pages
- 1144-1153
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2003541535
- Cited by
- 170
- References
- 1
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.